IL270457A - - Google Patents
Info
- Publication number
- IL270457A IL270457A IL27045719A IL27045719A IL270457A IL 270457 A IL270457 A IL 270457A IL 27045719 A IL27045719 A IL 27045719A IL 27045719 A IL27045719 A IL 27045719A IL 270457 A IL270457 A IL 270457A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Radiology & Medical Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502288P | 2017-05-05 | 2017-05-05 | |
| US201762545945P | 2017-08-15 | 2017-08-15 | |
| PCT/US2018/031233 WO2018204872A2 (en) | 2017-05-05 | 2018-05-04 | Igf-1r monoclonal antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270457A true IL270457A (https=) | 2020-01-30 |
| IL270457B1 IL270457B1 (en) | 2024-07-01 |
| IL270457B2 IL270457B2 (en) | 2024-11-01 |
Family
ID=64016737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270457A IL270457B2 (en) | 2017-05-05 | 2018-05-04 | R1–IGF monoclonal antibodies and their use |
| IL313115A IL313115A (en) | 2017-05-05 | 2018-05-04 | R1–IGF monoclonal antibodies and their use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313115A IL313115A (en) | 2017-05-05 | 2018-05-04 | R1–IGF monoclonal antibodies and their use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11433148B2 (https=) |
| EP (1) | EP3638320A4 (https=) |
| JP (2) | JP7191938B2 (https=) |
| KR (2) | KR20200004861A (https=) |
| CN (1) | CN110891614A (https=) |
| AU (2) | AU2018261890B2 (https=) |
| BR (1) | BR112019023249A8 (https=) |
| CA (1) | CA3062538A1 (https=) |
| CL (1) | CL2019003169A1 (https=) |
| IL (2) | IL270457B2 (https=) |
| MA (1) | MA49398A (https=) |
| MX (1) | MX2024006675A (https=) |
| RU (1) | RU2019139434A (https=) |
| WO (1) | WO2018204872A2 (https=) |
| ZA (1) | ZA201908072B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102612882B1 (ko) | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
| CA3062538A1 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| EA202191556A1 (ru) * | 2018-12-03 | 2021-10-14 | Фьюжн Фармасьютикалз Инк. | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек |
| JP7036996B2 (ja) | 2019-10-18 | 2022-03-15 | 日本メジフィジックス株式会社 | Ｒｉ標識されたヒト化抗体 |
| WO2021142231A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| BR112022013678A2 (pt) * | 2020-01-10 | 2022-11-16 | Fusion Pharmaceuticals Inc | Quelatos macrocíclicos e seus usos |
| IL295999A (en) * | 2020-03-23 | 2022-10-01 | Fusion Pharmaceuticals Inc | Radioimmunoconjugates designed for 3fgfr and their use |
| AU2021241682B2 (en) * | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| CN119792512A (zh) * | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| WO2023070202A1 (en) * | 2021-10-25 | 2023-05-04 | Fusion Pharmaceuticals Inc. | Claudin 18.2-targeted compounds and uses thereof |
| TW202325344A (zh) * | 2021-11-02 | 2023-07-01 | 加拿大商融合製藥公司 | 治療癌症之方法 |
| AU2023330112A1 (en) * | 2022-08-22 | 2025-03-13 | Abdera Therapeutics Inc. | Vhh antibody dota conjugates |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024216389A1 (en) * | 2023-04-20 | 2024-10-24 | Fusion Pharmaceuticals Inc. | Claudin 18.2-targeted compounds and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175343A (en) | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4889931A (en) | 1988-09-27 | 1989-12-26 | Salutar, Inc. | Manganese (II) chelate manufacture |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0382583B1 (en) | 1989-02-10 | 1996-01-17 | Celltech Therapeutics Limited | Aza macrocycles and processes for their preparation |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| US6274713B1 (en) | 1989-04-07 | 2001-08-14 | Salutar, Inc. | Polychelants |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US7385041B2 (en) | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
| CA2044737A1 (en) | 1990-06-18 | 1991-12-19 | Jaime Simon | Use of macrocyclic aminophosphonic acid complexes as imaging agents |
| US5386011A (en) | 1990-12-27 | 1995-01-31 | Abbott Laboratories | Hexapeptide anaphylatoxin-receptor ligands |
| GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| EP1138334A3 (en) | 1992-06-09 | 2002-04-03 | Neorx Corporation | Pretargeting methods and compounds |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| GB9504922D0 (en) | 1995-03-10 | 1995-04-26 | Nycomed As | Process |
| US20010023288A1 (en) * | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| IT1291624B1 (it) | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
| IT1304501B1 (it) | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
| WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| DE10002939C1 (de) | 2000-01-13 | 2001-09-20 | Schering Ag | Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln |
| US20020052354A1 (en) | 2000-01-27 | 2002-05-02 | Schering Ag | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction |
| US6264966B1 (en) | 2000-02-22 | 2001-07-24 | Concat, Ltd. | Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
| ATE271396T1 (de) | 2000-05-12 | 2004-08-15 | Univ Hospital | Prochelators von radiometall markierten molekülen |
| EP1390081A2 (en) | 2001-01-08 | 2004-02-25 | Neorx Corporation | Therapeutic and diagnostic compounds, compositions, and methods |
| EP1385556A4 (en) * | 2001-05-02 | 2005-10-19 | Univ Missouri System At Columb | PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS |
| DE10135355C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
| DE10135356C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
| TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
| AU2003261398A1 (en) | 2002-08-06 | 2004-02-23 | Epix Pharmaceuticals, Inc. | Peptide aggregates |
| DE10250870A1 (de) | 2002-10-31 | 2004-05-13 | Switch Biotech Ag | Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung |
| JP2006517558A (ja) | 2003-02-13 | 2006-07-27 | ブラッコ イメージング エッセ ピ ア | コントラスト増強ｘ線位相画像診断 |
| NZ542371A (en) | 2003-03-19 | 2008-10-31 | Universitatsspital Basel | Radiolabeled conjugates based on substance P and the uses thereof |
| WO2005001415A2 (en) | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| JP4262545B2 (ja) | 2003-07-09 | 2009-05-13 | 三菱電機株式会社 | カスコード接続回路及びその集積回路 |
| CA2526556C (en) * | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| JP2007505315A (ja) | 2003-09-12 | 2007-03-08 | インヴィトロジェン コーポレーション | 多重結合および活性アッセイ |
| WO2005060981A2 (en) | 2003-12-19 | 2005-07-07 | Schering Corporation | Pharmaceutical compositions |
| WO2005079803A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| WO2006015318A2 (en) | 2004-07-30 | 2006-02-09 | Biogen Idec Inc. | Antibody conjugated to a drug moiety via a poptidic linker |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20060222595A1 (en) | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
| JP2009509915A (ja) | 2005-07-15 | 2009-03-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ペルフルオロアルキル含有錯体、ならびにｎｍｒ、ｘ線および放射線診断、さらに放射線治療のための造影剤としてのその使用法 |
| US7618957B2 (en) | 2005-07-15 | 2009-11-17 | Bayer Schering Pharma Aktiengesellschaft | Perfluoroalkyl-containing complexes, process for their production as well as their use |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US20080058636A1 (en) | 2005-12-29 | 2008-03-06 | Epix Pharmaceuticals, Inc. | Methods of myocardial imaging |
| EP2065057A3 (en) | 2006-03-15 | 2009-08-12 | Mallinckrodt Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| US7612178B2 (en) * | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
| US7777029B2 (en) | 2006-05-02 | 2010-08-17 | San Diego State University (Sdsu) Foundation | Bifunctional chelators for sequestering lanthanides |
| JP2010500417A (ja) | 2006-08-11 | 2010-01-07 | ライフ テクノロジーズ コーポレーション | センサータンパク質及びアッセイ方法 |
| US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| GB0624587D0 (en) | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
| CA2676413A1 (en) | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| WO2008134289A2 (en) | 2007-04-26 | 2008-11-06 | Mallinckrodt Inc. | High relaxivity coordinatively unsaturated lanthanide complexes |
| ES2676598T3 (es) | 2007-08-27 | 2018-07-23 | Liebel-Flarsheim Company Llc | Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa |
| CA2697612A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
| EP2100900A1 (en) * | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| DE102008045937B4 (de) | 2008-04-11 | 2017-01-26 | Johannes-Gutenberg-Universität Mainz | Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons |
| CN102065895A (zh) * | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
| US8546531B2 (en) | 2008-07-16 | 2013-10-01 | The General Hospital Corporation | Methods and reagents for preparing multifunctional probes |
| EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| EP2362784A2 (en) | 2008-11-06 | 2011-09-07 | Luisa Bracci | Neurotensin-derived branched peptides and uses thereof |
| WO2010088527A2 (en) | 2009-01-30 | 2010-08-05 | Mayo Foundation For Medical Education And Research | Peptides and nanoparticles for therapeutic and diagnostic applications |
| EP2408790A1 (en) | 2009-03-19 | 2012-01-25 | Wyeth LLC | Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof |
| JP2012531212A (ja) * | 2009-07-03 | 2012-12-10 | アビペップ ピーティーワイ リミテッド | イムノコンジュゲート及びその作製方法 |
| US20120107248A1 (en) | 2009-07-08 | 2012-05-03 | Mayo Foundation For Medical Education And Research | Imaging gastrointestinal volumes and motility |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| WO2011090492A1 (en) * | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| EP2397466B1 (en) | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| RU2013121799A (ru) * | 2010-10-14 | 2014-11-20 | Конинклейке Филипс Электроникс Н.В. | Набор для претаргетинга, способ и агенты, применяемые в нем |
| US12097269B2 (en) | 2010-10-27 | 2024-09-24 | Vikas Kundra | Dual mode gadolinium nanoparticle contrast agents |
| FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
| CA2827170A1 (en) * | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| DK2721045T3 (en) | 2011-06-20 | 2017-07-24 | Radiomedix Inc | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS |
| FR2976825B1 (fr) | 2011-06-22 | 2014-02-21 | Total Sa | Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers |
| EP2604281B1 (en) | 2011-12-14 | 2014-07-30 | Centre National de la Recherche Scientifique (CNRS) | Clicked somatostatin conjugated analogs for biological applications |
| KR20130083592A (ko) | 2012-01-13 | 2013-07-23 | 현대약품 주식회사 | 치환된 피페리딘 유도체 및 이의 제조방법 |
| EP2852685A1 (en) * | 2012-03-30 | 2015-04-01 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
| EP2861723A4 (en) | 2012-06-14 | 2016-01-20 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS |
| CN102743770B (zh) | 2012-06-18 | 2017-07-21 | 申宝忠 | 一种靶向性分子成像探针及活体分子成像方法 |
| WO2014037498A2 (en) | 2012-09-07 | 2014-03-13 | Bracco Imaging Spa | Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri. |
| US9931412B2 (en) | 2013-02-08 | 2018-04-03 | The Regents Of The University Of Michigan | Targeted theranostics |
| CN105164136B (zh) | 2013-05-06 | 2017-12-22 | 默克专利股份公司 | 作为激酶抑制剂的大环化合物 |
| WO2015023979A1 (en) | 2013-08-16 | 2015-02-19 | Equip, Llc | Discrete peg constructs |
| US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| EP3068443B1 (en) | 2013-11-12 | 2019-04-10 | Centre for Probe Development and Commercialization | Residualizing linkers and uses thereof |
| WO2015085005A1 (en) | 2013-12-03 | 2015-06-11 | The General Hospital Corporation | Molecular imaging probes |
| FR3015547B1 (fr) | 2013-12-20 | 2016-01-01 | Total Sa | Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| LT3129406T (lt) | 2014-04-11 | 2019-04-10 | Medimmune, Llc | Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus |
| SI3134127T1 (sl) | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| CA2949365A1 (en) | 2014-05-16 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
| WO2016016329A1 (en) | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
| BE1021191B1 (fr) | 2014-08-29 | 2015-10-27 | Anmi S.A. | Kit pour radiomarquage. |
| GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| DE102014115154A1 (de) | 2014-10-17 | 2016-04-21 | SCV-SpezialChemikalien-Vertrieb GmbH | Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen |
| ES2981335T3 (es) | 2014-11-25 | 2024-10-08 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| WO2017120193A1 (en) | 2016-01-04 | 2017-07-13 | University Of Kansas | Drug delivery compositions and methods |
| US10758634B2 (en) * | 2016-03-18 | 2020-09-01 | Wake Forest University | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography |
| KR102612882B1 (ko) | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
| CA3062538A1 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| EP4204011A4 (en) * | 2020-08-27 | 2025-06-18 | Centre for Probe Development And Commercialization (CPDC) | Radiopharmaceutical and methods |
| EP4436979A1 (en) * | 2021-11-26 | 2024-10-02 | Full-Life Technologies HK Limited | Cleavable radioligands for targeting cell surface receptors and uses thereof |
-
2018
- 2018-05-04 CA CA3062538A patent/CA3062538A1/en active Pending
- 2018-05-04 KR KR1020197036028A patent/KR20200004861A/ko not_active Ceased
- 2018-05-04 AU AU2018261890A patent/AU2018261890B2/en active Active
- 2018-05-04 BR BR112019023249A patent/BR112019023249A8/pt unknown
- 2018-05-04 IL IL270457A patent/IL270457B2/en unknown
- 2018-05-04 US US15/971,980 patent/US11433148B2/en active Active
- 2018-05-04 MA MA049398A patent/MA49398A/fr unknown
- 2018-05-04 WO PCT/US2018/031233 patent/WO2018204872A2/en not_active Ceased
- 2018-05-04 EP EP18794036.6A patent/EP3638320A4/en not_active Withdrawn
- 2018-05-04 KR KR1020247036035A patent/KR20240160664A/ko active Pending
- 2018-05-04 CN CN201880039129.XA patent/CN110891614A/zh active Pending
- 2018-05-04 JP JP2020511869A patent/JP7191938B2/ja active Active
- 2018-05-04 RU RU2019139434A patent/RU2019139434A/ru unknown
- 2018-05-04 IL IL313115A patent/IL313115A/en unknown
-
2019
- 2019-11-05 MX MX2024006675A patent/MX2024006675A/es unknown
- 2019-11-05 CL CL2019003169A patent/CL2019003169A1/es unknown
- 2019-12-04 ZA ZA2019/08072A patent/ZA201908072B/en unknown
-
2022
- 2022-07-28 US US17/876,272 patent/US20230052140A1/en active Pending
- 2022-12-06 JP JP2022194891A patent/JP2023025209A/ja active Pending
-
2025
- 2025-06-06 AU AU2025204253A patent/AU2025204253A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019003169A1 (es) | 2020-08-14 |
| AU2018261890B2 (en) | 2025-03-20 |
| JP2023025209A (ja) | 2023-02-21 |
| EP3638320A4 (en) | 2021-01-20 |
| WO2018204872A2 (en) | 2018-11-08 |
| ZA201908072B (en) | 2023-04-26 |
| EP3638320A2 (en) | 2020-04-22 |
| JP2020518674A (ja) | 2020-06-25 |
| US11433148B2 (en) | 2022-09-06 |
| AU2025204253A1 (en) | 2025-06-26 |
| RU2019139434A3 (https=) | 2021-06-17 |
| WO2018204872A3 (en) | 2018-12-13 |
| JP7191938B2 (ja) | 2022-12-19 |
| BR112019023249A2 (pt) | 2020-06-02 |
| IL270457B2 (en) | 2024-11-01 |
| US20190083662A1 (en) | 2019-03-21 |
| NZ759831A (en) | 2025-05-30 |
| MA49398A (fr) | 2020-04-22 |
| KR20200004861A (ko) | 2020-01-14 |
| RU2019139434A (ru) | 2021-06-07 |
| MX2024006675A (es) | 2024-06-24 |
| BR112019023249A8 (pt) | 2021-02-23 |
| US20230052140A1 (en) | 2023-02-16 |
| CA3062538A1 (en) | 2018-11-08 |
| IL270457B1 (en) | 2024-07-01 |
| KR20240160664A (ko) | 2024-11-11 |
| AU2018261890A1 (en) | 2019-11-28 |
| IL313115A (en) | 2024-07-01 |
| CN110891614A (zh) | 2020-03-17 |